Seribantumab

Seribantumab
Monoclonal antibody
Type	?
Source	Human
Target	HER3
Clinical data
Other names	MM-121
ATC code	none;
Identifiers
CAS Number	1334296-12-6;
IUPHAR/BPS	8297;
ChemSpider	none;
UNII	1N3L70MDFX;
KEGG	D11777;
Chemical and physical data
Formula	C6340H9810N1690O1986S52
Molar mass	143151.18 g·mol−1

Seribantumab (INN;^[1] development code MM-121) is a monoclonal antibody designed for the treatment of cancer.^[2] It binds to extracellular domain of HER3 blocking NRG1 binding and thereby preventing the activation of the receptor.^[3]

This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.

^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association.
^ Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y (August 2022). "Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?". Biomedicines. 10 (9): 2113. doi:10.3390/biomedicines10092113. PMC 9495728. PMID 36140214.

[1] World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).

[2] Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association.

[pmid36140214-3] Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y (August 2022). "Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?". Biomedicines. 10 (9): 2113. doi:10.3390/biomedicines10092113. PMC 9495728. PMID 36140214.

[1]

[2]

[3]